Effects of pegylated interferon/ribavirin on bone turnover markers in HIV/Hepatitis C virus-coinfected patients

Roger Bedimo, Minhee Kang, Pablo Tebas, Edgar T. Overton, Kimberly Hollabaugh, Grace Mccomsey, Debika Bhattacharya, Christopher Evans, Todd T. Brown, Babafemi Taiwo

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

HIV/hepatitis C virus (HCV) patients have a 3-fold increased fracture incidence compared to uninfected patients. The impact of HCV therapy on bone health is unclear. We evaluated bone turnover markers (BTM) in well-controlled (HIV RNA

Original languageEnglish (US)
Pages (from-to)325-328
Number of pages4
JournalAIDS Research and Human Retroviruses
Volume32
Issue number4
DOIs
StatePublished - Apr 1 2016

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Effects of pegylated interferon/ribavirin on bone turnover markers in HIV/Hepatitis C virus-coinfected patients'. Together they form a unique fingerprint.

  • Cite this

    Bedimo, R., Kang, M., Tebas, P., Overton, E. T., Hollabaugh, K., Mccomsey, G., Bhattacharya, D., Evans, C., Brown, T. T., & Taiwo, B. (2016). Effects of pegylated interferon/ribavirin on bone turnover markers in HIV/Hepatitis C virus-coinfected patients. AIDS Research and Human Retroviruses, 32(4), 325-328. https://doi.org/10.1089/aid.2015.0204